Pfizer Inc
PFE: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$72.00 | Fjzbr | Xsjsqgbw |
Pfizer Earnings: Seagen Sales Help Offset Lost Covid Sales as Pipeline Strengthens
We are holding steady to our $42 fair value estimate for Pfizer following slightly better-than-expected second-quarter results. We continue to view the stock as undervalued, with the market not fully appreciating the firm’s cost-cutting and developing pipeline, which reinforce Pfizer’s wide moat.